$ONC
BeiGene, Ltd. Stock $onc

$onc Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000165130823000068 Filed on May 04, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q4
Revenue	$595.3M	$447.8M	$2.698B
YoY Change	74.27%	46.04%	98.0%
Cost Of Revenue	$95.99M	$81.79M	$501.9M
YoY Change	34.87%	25.37%	52.43%
Gross Profit	$499.3M	$366.0M	$2.196B
YoY Change	84.64%	51.63%	112.52%
Gross Profit Margin	83.87%	81.74%	81.39%
Selling, General & Admin	$395.0M	$328.5M	$2.367B
YoY Change	19.2%	11.52%	7.91%
% of Gross Profit	79.12%	89.75%	107.81%
Research & Development	$422.8M	$408.6M	$3.135B
YoY Change	11.78%	4.79%	10.96%
% of Gross Profit	84.68%	111.63%	142.76%
Depreciation & Amortization	$21.31M	$20.01M
YoY Change	47.34%	20.55%
% of Gross Profit	4.27%	5.47%
Operating Expenses	$817.8M	$737.1M	$5.519B
YoY Change	15.25%	7.68%	6.59%
Operating Profit	-$318.7M	-$371.3M	-$3.323B
YoY Change	-27.47%	-16.25%	-19.82%
Interest Expense	-$406.4M	$102.6M	$246.5M
YoY Change	-50.21%	373.18%	-307.01%
% of Operating Profit
Other Income/Expense, Net	-$63.82M	$18.30M	-$1.219M
YoY Change	-50.76%	52.95%	-524.74%
Pretax Income	-$367.5M	-$336.9M	-$3.078B
YoY Change	-34.1%	-20.01%	-27.82%
Income Tax	$13.67M	$11.49M	$130.8M
% Of Pretax Income
Net Earnings	-$381.1M	-$348.4M	-$3.208B
YoY Change	-33.3%	-19.77%	-24.46%
Net Earnings / Revenue	-64.03%	-77.81%	-118.93%
Basic Earnings Per Share	-$0.28	-$0.26
Diluted Earnings Per Share	-$0.28	-$0.26	-$2.38
COMMON SHARES
Basic Shares Outstanding	1.363B shares	1.356B shares	1.350B shares
Diluted Shares Outstanding	1.360B shares	1.354B shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$24.77B	$24.32B	$26.79B
YoY Change	-10.91%	289.43%	304.86%
Cash & Equivalents	$3.410B	$3.539B	$3.870B
Short-Term Investments	$6.126B	$6.499B	$6.659B
Other Short-Term Assets	$2.615B	$3.875B	$6.136B
YoY Change	-77.7%	-72.35%	22575.15%
Inventory	$321.3M	$297.0M	$282.3M
Prepaid Expenses
Receivables	$299.3M	$309.6M	$173.2M
Other Receivables	$253.9M	$62.13M	$89.94M
Total Short-Term Assets	$4.401B	$4.704B	$5.207B
YoY Change	-30.64%	-32.29%	-31.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.032B	$925.4M	$845.9M
YoY Change	63.0%	48.14%	43.97%
Goodwill	$109.0K	$109.0K	$109.0K
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$30.02M	$32.37M	$27.71M
YoY Change	10.77%	44.26%	20.71%
Other Assets	$147.5M	$173.4M	$170.4M
YoY Change	12.67%	5.36%	4.52%
Total Long-Term Assets	$1.327B	$1.252B	$1.172B
YoY Change	28.57%	16.7%	13.58%
TOTAL ASSETS
Total Short-Term Assets	$4.401B	$4.704B	$5.207B
Total Long-Term Assets	$1.327B	$1.252B	$1.172B
Total Assets	$5.729B	$5.957B	$6.379B
YoY Change	-22.36%	-25.74%	-26.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$267.0M	$241.4M	$294.8M
YoY Change	13.92%	1.88%	12.34%
Accrued Expenses	$455.0M	$417.9M	$467.4M
YoY Change	0.17%	8.28%	-16.25%
Deferred Revenue	$159.0M	$185.5M	$213.9M
YoY Change	-2.67%	13.33%	14.11%
Short-Term Debt	$2.908B	$1.834B	$2.203B
YoY Change	20.64%	-25.84%	-15.99%
Long-Term Debt Due	3.053B cnies	1.935B cnies	2.269B cnies
YoY Change	19.72%	-25.06%	-16.73%
Total Short-Term Liabilities	$1.405B	$1.255B	$1.469B
YoY Change	0.48%	-8.85%	-8.19%
LONG-TERM LIABILITIES
Long-Term Debt	1.504B cnies	1.417B cnies	1.443B cnies
YoY Change	21.25%	10.86%	12.0%
Other Long-Term Liabilities	$43.12M	$45.62M	$46.10M
YoY Change	-10.97%	-11.98%	-15.01%
Total Long-Term Liabilities	$525.1M	$544.9M	$527.4M
YoY Change	-22.47%	-28.26%	-34.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.405B	$1.255B	$1.469B
Total Long-Term Liabilities	$525.1M	$544.9M	$527.4M
Total Liabilities	$1.930B	$1.799B	$1.996B
YoY Change	-7.01%	-15.75%	-16.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$7.810B	-$7.429B	-$7.080B
YoY Change	30.78%	37.56%	42.57%
Common Stock	$137.0K	$136.0K	$135.0K
YoY Change	2.24%	2.26%	1.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.799B	$4.157B	$4.383B
YoY Change
Total Liabilities & Shareholders Equity	$5.729B	$5.957B	$6.379B
YoY Change	-22.36%	-25.74%	-26.22%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$381.1M	-$348.4M	-$3.208B
YoY Change	-33.3%	-19.77%	-24.46%
Depreciation, Depletion And Amortization	$21.31M	$20.01M
YoY Change	47.34%	20.55%
Cash From Operating Activities	-$1.526B	-$563.8M	-$1.341B
YoY Change	10.88%	138.32%	-56.88%
INVESTING ACTIVITIES
Capital Expenditures	$1.006B	$125.6M	$861.3M
YoY Change	-316.47%	178.27%	-169.45%
Acquisitions
YoY Change
Other Investing Activities	$2.113B	$9.250M	-$3.814B
YoY Change	-57.86%	-99.55%	-1747.16%
Cash From Investing Activities	$1.107B	$241.1M	-$4.675B
YoY Change	-75.67%	14.58%	363.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$1.457M
YoY Change
Cash From Financing Activities	1.098B	-$19.87M	-891.3M
YoY Change	-827.69%	76.34%	-104.15%
NET CHANGE
Cash From Operating Activities	-1.526B	-$563.8M	-1.341B
Cash From Investing Activities	1.107B	$241.1M	-4.675B
Cash From Financing Activities	1.098B	-$19.87M	-891.3M
Net Change In Cash	678.5M	-$331.3M	-6.908B
YoY Change	-77.55%	1064.93%	-139.83%
FREE CASH FLOW
Cash From Operating Activities	-$1.526B	-$563.8M	-$1.341B
Capital Expenditures	$1.006B	$125.6M	$861.3M
Free Cash Flow	-$2.532B	-$689.4M	-$2.202B
YoY Change	177.82%	144.72%	17.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001651308
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-37686
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	BEIGENE, LTD.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1209416
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	c/o Mourant Governance Services (Cayman) Limited
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	94 Solaris Avenue, Camana Bay
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Grand Cayman
CY2023Q1	dei	Entity Address Country EntityAddressCountry	KY
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	KY1-1108
CY2023Q1	dei	City Area Code CityAreaCode	345
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	949-4123
CY2023Q1	dei	Security12b Title Security12bTitle	American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	BGNE
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1362652101	shares
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3538644000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3869564000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	159000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	196000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	294057000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	665251000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	309628000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	173168000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	296995000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	282346000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	264835000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	216553000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	4704318000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	5207078000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4963000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5277000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	925404000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	845946000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	108989000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	109960000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	39735000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	40616000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	173366000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	170413000	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	1252457000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1172212000	usd
CY2023Q1	us-gaap	Assets Assets	5956775000	usd
CY2022Q4	us-gaap	Assets Assets	6379290000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	241360000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	294781000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	417922000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	467352000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	185477000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	213861000	usd
CY2023Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	33929000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	25189000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24545000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24041000	usd
CY2023Q1	bgne	Research And Development Cost Share Liability Current Portion ResearchAndDevelopmentCostShareLiabilityCurrentPortion	69510000	usd
CY2022Q4	bgne	Research And Development Cost Share Liability Current Portion ResearchAndDevelopmentCostShareLiabilityCurrentPortion	114335000	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	544918000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	527407000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	281808000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	328969000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1254551000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1468528000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	206298000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	209148000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	37345000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	42026000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	32543000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34517000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	16061000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	15996000	usd
CY2023Q1	bgne	Research And Development Cost Share Liability Noncurrent Portion ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion	207052000	usd
CY2022Q4	bgne	Research And Development Cost Share Liability Noncurrent Portion ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion	179625000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	45619000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	46095000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	1799469000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1995935000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	9500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	9500000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1362652101	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1362652101	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1356140180	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1356140180	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	136000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	135000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11644957000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11540979000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-59014000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-77417000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7428773000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7080342000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4157306000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4383355000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5956775000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6379290000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	447801000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	306626000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	81789000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	65237000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	408584000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	389915000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	328499000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	294573000	usd
CY2023Q1	bgne	Amortization Of Intangible Assets Included In Operating Expenses AmortizationOfIntangibleAssetsIncludedInOperatingExpenses	187000	usd
CY2022Q1	bgne	Amortization Of Intangible Assets Included In Operating Expenses AmortizationOfIntangibleAssetsIncludedInOperatingExpenses	188000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	819059000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	749913000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-371258000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-443287000	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	16016000	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	10071000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	18303000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11967000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-336939000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-421249000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11492000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13949000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-348431000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-435198000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1354164760	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1354164760	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1332017262	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1332017262	shares
CY2023Q1	bgne	Earnings Per American Depository Share Diluted EarningsPerAmericanDepositoryShareDiluted	-3.34
CY2023Q1	bgne	Earnings Per American Depository Share Basic EarningsPerAmericanDepositoryShareBasic	-3.34
CY2022Q1	bgne	Earnings Per American Depository Share Diluted EarningsPerAmericanDepositoryShareDiluted	-4.25
CY2022Q1	bgne	Earnings Per American Depository Share Basic EarningsPerAmericanDepositoryShareBasic	-4.25
CY2023Q1	bgne	Weighted Average Number Of American Depository Shares Outstanding Basic WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic	104166520	shares
CY2023Q1	bgne	Weighted Average Number Of American Depository Shares Outstanding Diluted WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted	104166520	shares
CY2022Q1	bgne	Weighted Average Number Of American Depository Shares Outstanding Diluted WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted	102462866	shares
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-16974000	usd
CY2022Q1	bgne	Weighted Average Number Of American Depository Shares Outstanding Basic WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic	102462866	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-348431000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-435198000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	13347000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	9374000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	5056000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-9870000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-330028000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-435694000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-348431000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-435198000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20011000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16600000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	75322000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	65555000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-169000	usd
CY2023Q1	bgne	Amortization Of Research And Development Financing Liability AmortizationOfResearchAndDevelopmentFinancingLiability	-17398000	usd
CY2022Q1	bgne	Amortization Of Research And Development Financing Liability AmortizationOfResearchAndDevelopmentFinancingLiability	-21819000	usd
CY2023Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	36000	usd
CY2022Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	50000	usd
CY2023Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	575000	usd
CY2022Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	3544000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	136487000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-292554000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	13027000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3002000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	50408000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	16942000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-22589000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-35024000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-38681000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-78750000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-33066000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-39676000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	197000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1429000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-563777000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-236563000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	125585000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	45131000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1064000	usd
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	504000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	376962000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	331028000	usd
CY2023Q1	bgne	Payments To Purchase In Process Research And Development PaymentsToPurchaseInProcessResearchAndDevelopment	0	usd
CY2022Q1	bgne	Payments To Purchase In Process Research And Development PaymentsToPurchaseInProcessResearchAndDevelopment	75000000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	9250000	usd
CY2022Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	241063000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	210393000	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1457000	usd
CY2022Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2023Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	0	usd
CY2022Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	50000000	usd
CY2023Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	50000000	usd
CY2022Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	73147000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	31589000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	11880000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-19868000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-11267000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11311000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-331271000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-28437000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3875037000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4382887000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3543766000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4354450000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3538644000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4347162000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	159000	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	330000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4963000	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	6958000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	7616000	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	736000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	5017000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	6617000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	64013000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	62736000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4383355000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	28657000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	75322000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	18403000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-348431000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4157306000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	6132563000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	0	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	11880000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	65555000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-496000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-435198000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	5774152000	usd
CY2023Q1	bgne	Number Of Persons NumberOfPersons	2700	people
CY2023Q1	bgne	Product Candidate ProductCandidate	3	product
CY2023Q1	dei	Entity Number Of Employees EntityNumberOfEmployees	9400	employee
CY2023Q1	us-gaap	Number Of Countries In Which Entity Operates NumberOfCountriesInWhichEntityOperates	30	country
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating variable consideration in product sales and collaboration revenue arrangements, identifying separate accounting units and determining the standalone selling price of each performance obligation in the Company’s revenue arrangements, assessing the impairment of long-lived assets, valuation and recognition of share-based compensation expenses, realizability of deferred tax assets, estimating uncertain tax positions, valuation of inventory, estimating the allowance for credit losses, determining defined benefit pension plan obligations, measurement of right-of-use assets and lease liabilities and the fair value of financial instruments. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities and reported amounts of revenues and expenses. Actual results could differ from these estimates.</span></div>
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revision of prior period financial statements </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company evaluates the recoverability of its deferred tax assets on a jurisdiction-by-jurisdiction basis by assessing the adequacy of future expected taxable income from all sources, including reversal of temporary differences, forecasted operating earnings and available tax planning strategies in accordance with ASC 740. This assessment is subject to a high degree of subjectivity, as the sources of income rely heavily on estimates that are based on a number of factors, including historical experience and short-range and long-range business forecasts. A valuation allowance is provided when the Company determines that it is more-likely-than-not that some portion or all of a deferred tax asset will not be realized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to the third quarter of 2022, the Company determined that the majority of its net deferred tax assets (primarily in the U.S.) were realizable on a more-likely-than-not basis, primarily due to cumulative pre-tax income at the taxpaying entity and the weighting of available positive and negative evidence. Accordingly, no valuation allowance was previously recorded related to those deferred tax assets. In October 2022, in connection with the preparation of its condensed consolidated financial statements for the three and nine months ended September 30, 2022, the Company reassessed its position on the realizability of its net deferred tax assets and determined that the negative evidence associated with cumulative losses at the consolidated financial statement level are not able to be overcome by other positive evidence, and therefore, a valuation allowance should be applied to its net deferred tax asset balance. The Company determined the previous conclusion to not apply a valuation allowance to certain net deferred tax assets was an error. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with Staff Accounting Bulletin (SAB) No. 99, “Materiality,” and SAB No. 108, “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements,” the Company evaluated the error and determined that the related impact was not material to any of its previously issued financial statements, but that correcting the cumulative impact of the error would be significant to its statements of operations for the three and nine months ended September 30, 2022. Accordingly, the Company has revised the first quarter of 2022 condensed consolidated financial statements and related notes included herein to record a valuation allowance against the Company’s net deferred tax asset balance for all periods presented. A summary of revisions to previously reported financial statements is presented in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Revision of Prior Period Financial Statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> have been updated to reflect the revision. The Company will also correct previously reported financial information for this error in its future filings, as applicable.</span></div>
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13949000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-435198000	usd
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2022Q1	bgne	Earnings Per American Depository Share Diluted EarningsPerAmericanDepositoryShareDiluted	-4.25
CY2022Q1	bgne	Earnings Per American Depository Share Basic EarningsPerAmericanDepositoryShareBasic	-4.25
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-435198000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-435694000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-435198000	usd
CY2022Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	50000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	16942000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-78750000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1429000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-236563000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	6132563000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-435198000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	5774152000	usd
CY2022Q1	bgne	Number Of Products Initiated Marketing And Promotion NumberOfProductsInitiatedMarketingAndPromotion	5	product
CY2023Q1	bgne	Reimbursement Expense ReimbursementExpense	11583000	usd
CY2022Q1	bgne	Reimbursement Expense ReimbursementExpense	11711000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	5122000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	5473000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	298012000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3955000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	294057000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	674262000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9011000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	665251000	usd
CY2023Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	59673000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	57054000	usd
CY2023Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount	1081000	usd
CY2022Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount	336000	usd
CY2023Q1	us-gaap	Equity Method Investments EquityMethodInvestments	32368000	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	27710000	usd
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	108655000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	88957000	usd
CY2023Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	24582000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	20886000	usd
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	163758000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	172503000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	296995000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	282346000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	739603000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	723789000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	191097000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	171470000	usd
CY2023Q1	us-gaap	Construction In Progress Gross ConstructionInProgressGross	376898000	usd
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	293627000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	925404000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	845946000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	19025000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	15580000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	49664000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9929000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	39735000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	49551000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8935000	usd
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	5528000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	40616000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	986000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1020000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2945000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3928000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3928000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3928000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3678000	usd
CY2023Q1	bgne	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	21328000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	39735000	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2023Q1	bgne	Accounts Receivable Allowance For Credit Loss Exchange Rate Changes AccountsReceivableAllowanceForCreditLossExchangeRateChanges	0	usd
CY2022Q1	bgne	Accounts Receivable Allowance For Credit Loss Exchange Rate Changes AccountsReceivableAllowanceForCreditLossExchangeRateChanges	19000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11492000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13949000	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11965000	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	410000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	211000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	415000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	222000	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-241000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	433000	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	193000	usd
CY2023Q1	bgne	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	76403000	usd
CY2022Q4	bgne	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	71488000	usd
CY2023Q1	bgne	Prepaid Manufacturing Costs PrepaidManufacturingCosts	62571000	usd
CY2022Q4	bgne	Prepaid Manufacturing Costs PrepaidManufacturingCosts	58950000	usd
CY2023Q1	us-gaap	Prepaid Taxes PrepaidTaxes	20402000	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	20478000	usd
CY2023Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	21195000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	22777000	usd
CY2023Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	1335000	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	3039000	usd
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	5719000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3664000	usd
CY2023Q1	bgne	Short Term Deposits ShortTermDeposits	34837000	usd
CY2022Q4	bgne	Short Term Deposits ShortTermDeposits	1510000	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	42373000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	34647000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	264835000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	216553000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	109000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	109000	usd
CY2023Q1	bgne	Prepayment Of Long Term Asset PrepaymentOfLongTermAsset	19165000	usd
CY2022Q4	bgne	Prepayment Of Long Term Asset PrepaymentOfLongTermAsset	22025000	usd
CY2023Q1	bgne	Prepaid Supply Cost PrepaidSupplyCost	47763000	usd
CY2022Q4	bgne	Prepaid Supply Cost PrepaidSupplyCost	48642000	usd
CY2023Q1	us-gaap	Value Added Tax Receivable Noncurrent ValueAddedTaxReceivableNoncurrent	1428000	usd
CY2022Q4	us-gaap	Value Added Tax Receivable Noncurrent ValueAddedTaxReceivableNoncurrent	804000	usd
CY2023Q1	bgne	Rental Deposits And Other RentalDepositsAndOther	6954000	usd
CY2022Q4	bgne	Rental Deposits And Other RentalDepositsAndOther	7054000	usd
CY2023Q1	us-gaap	Long Term Investments LongTermInvestments	97947000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	91779000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	173366000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	170413000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	87950000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	184775000	usd
CY2023Q1	bgne	Accrued Liabilities External Research And Development AccruedLiabilitiesExternalResearchAndDevelopment	143137000	usd
CY2022Q4	bgne	Accrued Liabilities External Research And Development AccruedLiabilitiesExternalResearchAndDevelopment	139168000	usd
CY2023Q1	bgne	Accrued Expenses Commercial Activities AccruedExpensesCommercialActivities	48465000	usd
CY2022Q4	bgne	Accrued Expenses Commercial Activities AccruedExpensesCommercialActivities	51806000	usd
CY2023Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	28040000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	18815000	usd
CY2023Q1	bgne	Accrued Sales Rebates And Returns Current AccruedSalesRebatesAndReturnsCurrent	78732000	usd
CY2022Q4	bgne	Accrued Sales Rebates And Returns Current AccruedSalesRebatesAndReturnsCurrent	41817000	usd
CY2023Q1	bgne	Accrued Professional Fees And Other Current AccruedProfessionalFeesAndOtherCurrent	31598000	usd
CY2022Q4	bgne	Accrued Professional Fees And Other Current AccruedProfessionalFeesAndOtherCurrent	30971000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	417922000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	467352000	usd
CY2023Q1	bgne	Government Grants Or Incentives Received And Deferred Noncurrent GovernmentGrantsOrIncentivesReceivedAndDeferredNoncurrent	37576000	usd
CY2022Q4	bgne	Government Grants Or Incentives Received And Deferred Noncurrent GovernmentGrantsOrIncentivesReceivedAndDeferredNoncurrent	38176000	usd
CY2023Q1	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	7851000	usd
CY2022Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	7760000	usd
CY2023Q1	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	192000	usd
CY2022Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	159000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	45619000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	46095000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	281808000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	1935363000	cny
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	328969000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2268905000	cny
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	206298000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1416786000	cny
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	209148000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1442500000	cny
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	4574000	usd
CY2023Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	344000	usd
CY2022Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	1281000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-348431000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-435198000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1354164760	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1354164760	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1332017262	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1332017262	shares
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	75388000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	65555000	usd
CY2023Q1	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	76097000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	18403000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	18403000	usd
CY2023Q1	bgne	Restricted Net Assets Minimum Required Statutory Reserve Of Annual After Tax Profit Percentage RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage	0.10
CY2023Q1	bgne	Restricted Net Assets Required Statutory Reserve As Percentage Of Registered Capital RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital	0.50
CY2023Q1	bgne	Restricted Net Assets Minimum Required Statutory Reserve Of Annual After Tax Profit Percentage RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage	0.10
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	447801000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	306626000	usd

Files In Submission

Name	View Source	Status
bgne-20230331_lab.xml	Edgar Link	unprocessable
bgne-20230331_cal.xml	Edgar Link	unprocessable
0001651308-23-000068-index-headers.html	Edgar Link	pending
0001651308-23-000068-index.html	Edgar Link	pending
0001651308-23-000068.txt	Edgar Link	pending
0001651308-23-000068-xbrl.zip	Edgar Link	pending
bgne-20230331.htm	Edgar Link	pending
bgne-20230331.xsd	Edgar Link	pending
bgne-20230331_g1.jpg	Edgar Link	pending
exhibit101-secondamendment.htm	Edgar Link	pending
exhibit103-amendmentno2tor.htm	Edgar Link	pending
exhibit311-2023q1.htm	Edgar Link	pending
exhibit312-2023q1.htm	Edgar Link	pending
exhibit321-2023q1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
bgne-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bgne-20230331_htm.xml	Edgar Link	completed
bgne-20230331_def.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ONC
BeiGene, Ltd. Stock $onc

2023 Q2 Form 10-Q Financial Statement

#000165130823000068 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONC BeiGene, Ltd. Stock $onc

2023 Q2 Form 10-Q Financial Statement

#000165130823000068 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONC
BeiGene, Ltd. Stock $onc